ScripMergers and acquisitions usually happen in major global biopharma markets as a way to gain new technologies, R&D or commercial portfolios, expand a business or to beef up supply networks. But in S
ScripThe fourth quarter marked a continuation of weak earnings for many major South Korean pharma firms, hurt by factors including the continued impact of a long-running doctors’ protest against medical r
ScripIt is a time of challenges and uncertainties for the global biopharma industry and with the start of the second Trump Administration in the US, the international trade environment looks set to change
ScripMajor South Korean pharma firms have reported mixed earnings for the third quarter ended 30 September, with Yuhan logging strong earnings after the US approval of its novel lung cancer drug and Hanmi